Advertisement

Topics

Therapix Bioscience (TRPX) - Tackling neurology with cannabinoids

09:17 EDT 29 Jun 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Therapix Bioscience: Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on NASDAQ in the US 2.3m ADS (worth $13.8m). The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette’s in adults and THX-ULD01 is scheduled to begin Phase I trials for the treatment of mild cognitive impairment (MCI) in mid-2017. Both programs should qualify for a 505(b)(2) pathway to streamline approval. We arrive at an initial valuation of $38.4m or $10.97 per ADS.
ISIN: US88339A2033

Original Article: Therapix Bioscience (TRPX) - Tackling neurology with cannabinoids

NEXT ARTICLE

More From BioPortfolio on "Therapix Bioscience (TRPX) - Tackling neurology with cannabinoids"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...